Acceptability and efficacy of naltrexone for criminal justice‐involved individuals with opioid use disorder: a systematic review and meta‐analysis. (17th January 2020)

• Record Type: Journal Article
• Authors: Bahji, Anees; Carlone, David; Altomare, Josephine
• Is Part Of: Addiction. Volume 115:Number 8(2020)
• Page Start: 1413
• Page End: 1425
• Publication Date: 2020-01-17
• Subjects: Analgesics, opioid -- criminal justice‐involved individuals -- drug overdose -- naltrexone -- opioid‐related disorders -- treatment outcome; Alcoholism -- Periodicals; Drug addiction -- Periodicals; 616.86
• DOI: 10.1111/add.14946
• Languages: English
• ISSNs: 0965-2140

Abstract

Abstract: Background and aims: Criminal justice‐involved individuals carry a disproportionately higher burden of opioid use disorder (OUD) than those not involved with the criminal justice system, and are often unable to access opioid agonist therapies such as methadone and buprenorphine. The opioid receptor antagonist naltrexone (NTX) is effective for the prevention of relapse to OUD and may be more acceptable in criminal justice settings. The objectives of this review were to: (1) provide an overall summary effect across studies for the efficacy and acceptability of oral and injectable NTX for the treatment of OUD among criminal justice‐involved individuals and (2) examine systematic variations in study results to explain heterogeneity among study‐specific effects. Methods: Systematic review and meta‐analysis of 1045 patients across 11 studies (10 randomized controlled trials, one quasi‐experimental study). All available outcomes were pooled using random‐effects meta‐analysis. Subgroup analyses were conducted for oral and injectable naltrexone; meta‐regression analyses were conducted for socio‐demographic and study‐level characteristics. Results: NTX improved retention in treatment [risk ratio (RR) = 1.31; 95% confidence interval (CI) = 1.05, 1.63], reduced rates of re‐incarceration (RR = 0.70, 95% CI = 0.54–0.92), reduced opioid relapse (RR = 0.63, 95% CI = 0.53–0.76) and improved opioid abstinence (RR = 1.38, 95% CI = 1.16–1.65). While NTX was associated with a greater burden of adverse events overall (RR = 1.49, 95% CI = 1.13–1.95), the findings were inconclusive as to whether or not a difference was present for the number of serious adverse events or overdoses. Conclusions: Naltrexone appears to be efficacious and acceptable for the treatment of opioid use disorder among criminal justice‐involved individuals; however, the risk for adverse events must be weighed against the potential benefits.